PharmChem, Inc.
PCHM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | 0.00 | -0.25 | -2.59 |
| FCF Yield | 9.16% | 4.94% | 12.48% | 3.10% |
| EV / EBITDA | 7.26 | 10.85 | 6.20 | 15.56 |
| Quality | ||||
| ROIC | 59.98% | 34.17% | 23.42% | 60.02% |
| Gross Margin | 63.72% | 64.94% | 64.18% | 62.55% |
| Cash Conversion Ratio | 0.95 | 0.76 | 1.45 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.40% | -1.13% | -4.34% | 3.93% |
| Free Cash Flow Growth | 103.87% | -49.55% | 44.69% | -59.73% |
| Safety | ||||
| Net Debt / EBITDA | -0.91 | -1.42 | -2.97 | -1.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 9.69 | 5.38 | 13.00 | 34.25 |
| Cash Conversion Cycle | 49.91 | 78.77 | 38.88 | 34.93 |